Introduction {#sec1}
============

β-Lactam antibiotics ([Figure 1](#F1){ref-type="fig"}A), including penicillins (e.g. penicillin G), cephalosporins (e.g. cefazolin), monobactams and carbapenems (e.g. imipenem), are the most widely used agents for treating clinical bacterial infections \[[@B1]\]. Among these, carbapenems, featuring a five-membered ring fused to the β-lactam core structure, are an important class of β-lactam antibiotics widely used in the treatment of serious bacterial infections caused by bacteria expressing extended-spectrum β-lactamases (ESBLs) \[[@B2],[@B3]\]. However, the overuse of this class of antibiotic has led to decreased bacterial susceptibility towards these compounds, mostly via mechanisms such as antibiotic inactivation by carbapenemases, reduced bacterial membrane permeability, altered penicillin binding proteins (PBPs) and/or efflux of antibiotics \[[@B4]\]. Of these mechanisms, production of carbapenemases poses the most serious threat, not only because carbapenemase-producing bacteria tend to have higher level of resistance to carbapenems, but also because the carbapenemase gene in mobile genetic elements is easy to transfer across species, giving rise to nosocomial outbreaks of carbapenem-resistant pathogens \[[@B9]\]. According to amino acid homologies, carbapenemases have been classified into A, B and D groups in the Ambler system. Class A and D enzymes contain a catalytic serine residue in the active site to aid the hydrolysis of the C--N bond through formation of a covalent acyl-enzyme adduct, whereas class B enzymes (metallo-β-lactamases, MβLs) require the presence of zinc to activate water for nucleophilic attack on the substrate \[[@B10]\].

![Structures of representative β-lactam antibiotics and carboxylic acid inhibitors\
D-Captopril **1**, salicylic acid derivative **2**, ME1071 **3**, AMA **4**, D-(−)-tartaric acid **5**, fumaric acid **6**, pyridine-2,6-dicarboxylic acid **7** and *rac*-thiazolidine-2,4-dicarboxylic acid **8**.](bsr-38-bsr20180244-g1){#F1}

Currently, several inhibitors of serine-β-lactamases, including clavulanic acid, sulbactam and tazobactam have been clinically approved to work in synergy with β-lactams, while others (e.g. avibactam and MK-7655) are in clinical trial. While such combination therapy is useful in tackling infections due to serine-β-lactamases, there are currently no inhibitors approved for use against bacteria harbouring MβLs \[[@B11]\]. Of particular clinical importance, New Delhi metallo-β-lactamase-1 (NDM-1), first discovered in 2008 in a strain of *Klebsiella pneumoniae* isolated in India, is now one of the most abundant MβLs in clinic \[[@B15],[@B16]\]. It has been found in species of *Enterobacteriaceae, Acinetobacter baumannii, Vibrio cholerae, Stenotrophomonas* and *Pseudomonas aeruginosa*, and accounts for 60% of autochthonous human infection isolates according to a survey of data from 2009 to 2012 \[[@B16],[@B17]\]. Hence, a mechanistic study \[[@B18]\] of NDM-1 and the design of potent NDM-1 inhibitors for combination therapy are active areas for antimicrobial research \[[@B21]\].

Among the reported NDM-1 inhibitors, carboxylic acid-containing compounds are one of the most prominent categories \[[@B22],[@B23]\]. D-Captopril **1** ([Figure 1](#F1){ref-type="fig"}B) has been shown to be a potent competitive inhibitor of NDM-1 with *K*~i~ 1.3 μM \[[@B24],[@B25]\], while a salicylic acid derivative **2** was predicted to inhibit NDM-1 in a molecular docking study \[[@B26]\]. A maleic acid substitute ME1071 **3** was reported to inhibit NDM-1 with a *K*~i~ of 24 μM \[[@B27]\]. King et al. identified a natural product AMA **4** as a potent inactivator of NDM-1 with a *K*~i~ value of 11 nM and an IC~50~ of 4.0 μM \[[@B28],[@B29]\]. Hence, it is important to investigate whether even simpler carboxylic acid derivatives may have good inhibitory potency for further development of clinical NDM-1 inhibitors.

Isothermal titration calorimetry (ITC) is a powerful technique capable of measuring real-time heat change rates in enzyme-catalysed reactions, a parameter directly proportional to the reaction rate which has thus become widely used for enzyme thermodynamic and kinetic studies \[[@B30]\]. However, this technique has not received much attention in work on MβLs. We have recently developed an ITC assay to study the thermokinetics of a B3 subclass MβL L1 and our results demonstrate that the calorimetric approach is a simple and efficient method in evaluating the kinetics of β-lactam hydrolysis. It has the additional advantages of being able to provide valuable information on the thermodynamic nature of enzyme catalysis, being compatible with optically turbid bacterial suspensions in contrast with conventional UV spectroscopy \[[@B36]\]. In this work, we sought to apply this calorimetric approach to a mechanistic study of a clinically relevant NDM-1 in the B1 subclass of MβLs, using three representative β-lactams: penicillin G, cefazolin and imipenem. In the second part of this work, the inhibitory potencies of four low-molecular-weight dicarboxylic acid compounds on NDM-1 were investigated. Of the compounds studied, D-(−)-tartaric acid **5** and fumaric acid **6** are two natural dicarboxylates with structural resemblance to **3** and **4**. Pyridine-2,6-dicarboxylic acid **7** was reported to be an effective inhibitor of IMP-1 and CphA \[[@B37]\]. Recently, derivatives of **7** were demonstrated to be highly selective inhibitors for B1 MβLs \[[@B38]\]. Thiazolidine-2,4-dicarboxylic acid **8** was shown to have a powerful effect on CcrA, Imis and L1 activities \[[@B39],[@B40]\]. It is generally believed that carboxylate compounds exert the inhibitory effect via interaction with active site zinc atoms and current data have revealed a significant degree of selectivity of these compounds between different MβLs \[[@B39]\]. Hence, an evaluation of carboxylates **5--8** on NDM-1 provides valuable information for the exploration of promising scaffolds and the development of broad-spectrum inhibitors of MβLs. Given that NDM-1 remains a global challenge in medicinal chemistry, characterisation of this clinically important enzyme using a calorimetric approach will give strong support to ongoing studies on the mechanism and inhibition of NDM-1.

Materials and methods {#sec2}
=====================

Enzyme and reagents {#sec2-1}
-------------------

Antibiotics (\>98% purity) were purchased from Sigma--Aldrich Trading Co. Ltd (Shanghai, China). Compounds **1** (98% purity) and **5--7** were from the Aladdin Industrial Corporation (Shanghai, China). Compound **8** was from J&K Scientific Ltd (Beijing, China). All other chemicals were analytical grade. The expression plasmid pET26b--NDM-1 \[[@B41]\] for the production of recombinant NDM-1 enzyme was a kind gift from Professor Michael Crowder at Miami University, Florida, USA. *Escherichia coli* ATCC25922 was purchased from the American Type Culture Collection (ATCC). The clinical *E. coli* strain used was isolated from a blood culture of one individual patient in the First Affiliated Hospital of Xi'an Jiaotong University (Xi'an, China), and had previously been confirmed by DNA sequence to produce NDM-1 (unpublished data).

NDM-1 gene expression and protein purification {#sec2-2}
----------------------------------------------

Recombinant NDM-1 was produced and purified as previously described \[[@B41]\]. Briefly, recombinant *E. coli* cells containing the NDM-1 gene in pET26b plasmid were grown in Lysogeny Broth (LB) medium supplemented with 25 μg/ml kanamycin at 37°C and gene expression was induced by adding 1 mM IPTG and 50 μM ZnCl~2~. The culture was incubated overnight at 20°C before cells were harvested and then lysed by sonication. Protein was first loaded on a Q-Sepharose ion exchange column and eluted with a gradient of 0--500 mM NaCl in 30 mM Tris--HCl, pH 8.0. A Superdex 75 size exclusion column was used to further purify the target protein in the buffer of 30 mM Tris--HCl, pH 7.5 and 200 mM NaCl. The purity of fractions containing NDM-1 protein was checked using SDS--PAGE, and the concentration of purified protein was determined using UV-spectroscopy with extinction coefficient 27960 M^−1^ cm ^−1^ at 280 nm.

UV-spectroscopic assay {#sec2-3}
----------------------

IC~50~ values of compounds **1** and **5--8** were determined using a spectroscopic method \[[@B42]\]. Assays were carried out using an Agilent UV 8453 spectroscopy at 25°C, with 60 μM penicillin G as a substrate in a total volume of 1 ml buffer (50 mM Tris--HCl, pH 7.0, 100 mM NaCl). Reactions were initiated by addition of NDM-1 enzyme to a final concentration of 20 nM and changes in absorbance of penicillin G at 205 nm were recorded continuously for 30 s. Rates were also determined in the presence of inhibitor by pre-incubation with the enzyme for 30 min at RT before starting kinetic experiments. IC~50~ values were determined using GraphPad Prism5 software (GraphPadSoftware, La Jolla, CA, USA) by plotting percentage of inhibition against inhibitor concentration; average values from three measurements are reported.

Calorimetric assays {#sec2-4}
-------------------

Enzyme kinetics of NDM-1 and inhibition studies by carboxylic acid compounds were conducted using an ITC-200 calorimeter (Malvern Instruments Ltd., UK), with a reference cell loaded with deionised water and experiments carried out at 25°C with a stirring speed of 750 rpm.

To obtain the apparent enthalpy change (Δ*H*~app~) of enzyme-catalysed hydrolysis of antibiotics (penicillin G, cefazolin or imipenem), experiments were performed by injecting 20 μl of 1 mM antibiotic solution, preloaded in the syringe, into a sample cell filled with 210 μl of 50 nM purified NDM-1 in buffer of 50 mM Tris--HCl, pH 7.0, 100 mM NaCl. Real-time changes of heat-flow were recorded continuously until return to baseline. Control experiments were performed by titrating substrate to buffer and using those data in corrections for heat of dilution before values of Δ*H*~app~ were determined using the embedded Origin software, by dividing integrated heat by the molar quantity of substrate converted according to ([eqn 1](#e1){ref-type="disp-formula"}), where d*Q*/d*t* is the rate of heat production, *V* is the volume of the sample cell and \[*S*\]~*t*\ =\ 0~ is the substrate concentration: $$\Delta H = \frac{f_{t = 0}^{\infty}\frac{\text{dQ}}{\text{dt}}dt}{\left( {\text{V}\left\lbrack \text{S} \right\rbrack_{({t = 0})}} \right)}$$

Experiments were also repeated in HEPES and phosphate buffers and the intrinsic enthalpy change (Δ*H*~int~) of the reactions calculated according to ([eqn 2](#e2){ref-type="disp-formula"}) by plotting the measured Δ*H*~app~ as a function of Δ*H*~ion~, where Δ*H*~ion~ is the ionisation enthalpy of the buffer used and *n* represents the number of exchanging protons. The values of Δ*H*~ion~ used in the calculation were Δ*H*~ion~ (Tris--HCl) = 11.34 kcal/mol, Δ*H*~ion~ (HEPES) = 4.88 kcal/mol and Δ*H*~ion~ (phosphate) = 0.86 kcal/mol \[[@B43]\]. $$\Delta H_{\text{app}} = \Delta H_{int} + n\,\Delta H_{\text{ion}}$$

For steady-state kinetics of NDM-1, experiments were conducted in multi-injection mode, with 10 nM NDM-1 in the sample cell and 10 mM antibiotic (penicillin G, cefazolin or imipenem) in the syringe, both in buffer of 50 mM Tris--HCl, pH 7.0, 100 mM NaCl. Successive injections of antibiotic into the sample cell were made at 120 s intervals. Following ([eqn 3](#e3){ref-type="disp-formula"}), the change in thermal power (d*Q*/d*t*) from each titration was converted into the reaction rate (*υ*). These rates were used to fit to the Michaelis--Menten equation ([eqn 4](#e4){ref-type="disp-formula"}) to obtain the kinetic parameters *K*~M~ (Michaelis--Menten constant) and *k*~cat~ (turnover rates), where \[*E*\]~tot~ is the total concentration of active enzyme. $$\upsilon = \frac{\text{dP}}{\text{dt}} = \frac{1}{\text{V}\Delta H_{\text{app}}} \cdot \frac{\text{dQ}}{\text{dt}}$$ $$\upsilon = \frac{k_{\text{cat}}\left\lbrack \text{E} \right\rbrack_{\text{tot}}\left\lbrack \text{S} \right\rbrack}{K_{\text{M}} + \left\lbrack \text{S} \right\rbrack}$$

Inhibition studies for NDM-1 with compounds **1** and **5--8** using calorimetric assay were performed by pre-incubating NDM-1 with the corresponding compound for 30 min prior to starting a multi-injection experiment with penicillin G, as described above. The concentrations of substrate and NDM-1 were the same as for the kinetic assay. Concentrations used for **1** were 2 and 20 μM, for **5** were 1 and 2 mM, for **6** were 100 μM and 1.5 mM, for **7** were 1 and 5 μM and for **8** were 2 and 10 μM. Competitive (*K*~ic~) and uncompetitive (*K*~iu~) inhibition constant values for each inhibitor were obtained by fitting calculated reaction rates (*υ*) at different inhibitor concentrations to ([eqn 5](#e5){ref-type="disp-formula"}) using nonlinear regression analysis in Origin software (embedded with ITC), with *K*~ic~ and *K*~iu~ set as shared parameters between all datasets, inhibitor concentration \[*I*\], \[*E*\]~tot~, \[*S*\] as independent variables and *υ* as dependent variable. $$\upsilon = \frac{k_{\text{cat}}\left\lbrack E \right\rbrack_{\text{tot}}\left\lbrack \text{S} \right\rbrack}{\left\lbrack \text{S} \right\rbrack\left( 1 + \frac{\left\lbrack \text{I} \right\rbrack}{K_{\text{iu}}} \right) + \text{K}_{\text{m}}\left( 1 + \frac{\left\lbrack \text{I} \right\rbrack}{K_{\text{ic}}} \right)}$$

Cell-based calorimetric assays were performed using a clinical *E. coli* strain expressing NDM-1 gene (*E. coli--*NDM-1) and a reference bacterial strain ATCC 25922 (β-lactamase negative). Experiments were performed as above, except that bacterial suspensions were added to the sample cell of the calorimeter at a concentration of 1 OD in the absence and presence of 500 μM **1, 7** and **8**, prepared in 50 mM Tris--HCl, pH 7.0, 100 mM NaCl buffer supplement with 0.1% Triton. The raw calorimetric signal was obtained after all penicillin G (20 μl of 1 mM) was injected.

MIC determinations {#sec2-5}
------------------

The efficacies of compounds **1, 7** and **8** to work in synergy with an antibiotic were investigated by determining the minimum inhibitory concentrations (MICs) of imipenem towards the above clinical *E. coli*--NDM-1 strain using a broth microdilution method according to guidelines of the Clinical and Laboratory Standards Institute (CLSI) \[[@B44]\]. Single colonies of *E. coli*--NDM-1 were used to inoculate Mueller--Hinton medium and were grown at 37°C overnight. A volume of 100 μl of diluted bacteria culture at a density of 10^6^ colony forming units (CFU) per ml was added to a series of 2-fold diluted imipenem solutions prepared in 100 μl Mueller--Hinton medium, in the presence of compounds **1, 7** and **8** at 0, 200 and 400 μM. Results were obtained after incubating the microtitre plate at 37°C for a further 18 h and turbidity of bacterial growth was recorded using a plate reader.

Results and discussion {#sec3}
======================

A single injection calorimetric experiment was performed to record the real-time heat change associated with NDM-1 catalysed hydrolysis of β-lactams and a raw calorimetric trace of titrating 20 μl of 1 mM penicillin G into 210 μl of 50 nM NDM-1 in Tris--HCl, pH 7.0 buffer is shown ([Figure 2](#F2){ref-type="fig"}A). The negative change in heat-flow shows the reaction is exothermic. The largest displacement of the baseline (120--160 s, [Figure 2](#F2){ref-type="fig"}A) corresponds to the maximum catalytic rate under enzyme saturation conditions, while the decay portion of the curve (160--300 s) reflects gradual depletion of the substrate until fully consumed. The apparent enthalpy change (Δ*H*~app~) of each reaction was calculated by integrating the area under the entire titration curve and normalised for substrate consumed (in moles). The Δ*H*~app~ values for NDM-1 catalysed hydrolysis of penicillin G, cefazolin and imipenem at pH 7.0, 25°C were determined to be --27.9, --28.3 and --32.5 kcal/mol, respectively ([Table 1](#T1){ref-type="table"}). The measured heat reflects the total enthalpy of all events in the reaction vessel, including both the intrinsic enthalpy change of the reaction and the ionisation enthalpy of the buffer used. To determine the Δ*H*~int~ of each antibiotic, the reaction was performed in buffers having different ionisation enthalpies at pH 7.0. By plotting Δ*H*~app~ as a function of Δ*H*~ion~ specific to each buffer used ([Figure 2](#F2){ref-type="fig"}B), it is apparent that there is a decrease in Δ*H*~app~ with the increase of Δ*H*~ion~, indicating NDM-1 catalysed hydrolysis of penicillin G involves exchanging of proton(s) with the buffer solution. The same result was obtained for cefazolin and imipenem. The number of exchanging protons (*n*) was determined as the slope of the fitted plots, −0.87 (± 0.10) for penicillin G and −1.24 (± 0.02) for imipenem, in agreement with previous data on metallo-β-lactamase L1 that approximately one proton is released to buffer during catalysis with the divergence from unity depending on the p*K*~a~ of the amino group in the hydrolysis product \[[@B36]\]. However, the hydrolysis of cefazolin by NDM-1 apparently involves a different mechanism, with two protons (*n* = −1.89 ± 0.04) being taken up by the buffer. The intrinsic enthalpy (Δ*H*~int~) of each antibiotic was determined as the *Y*-axis intercept, and values were −18.3 ± 0.73 kcal/mol for penicillin G, −18.4 ± 0.12 kcal/mol for imipenem, and a significantly lower value of −5.20 ± 0.04 kcal/mol for cefazolin. Based on existing data, the hydrolyses of these β-lactams by NDM-1 involve different processes \[[@B45]\]. Since NDM-1 catalysed hydrolysis of penicillin G and imipenem at pH 7.0 are accompanied by a similar intrinsic enthalpy change and both are associated with the release of one proton, it is reasonable to speculate that these two compounds use the same mechanism and the proton released is likely derived from ionisation of the new carboxylic acid generated at C-7 after β-lactam ring opening ([Figure 3](#F3){ref-type="fig"}A,B). In comparison, a significant smaller intrinsic enthalpy change and one additional proton exchanged during cefazolin hydrolysis indicates a different pathway is adopted by NDM-1 in the hydrolysis of this compound. Indeed, it is known that for some cephalosporins, following the opening of the β-lactam ring, the anionic nitrogen intermediate is expected to undergo β-elimination of the leaving group with fragmentation of the initial product \[[@B45]\]. Hence, it is possible that the intrinsic enthalpy change of cefazolin turnover also involves heat change in this subsequent elimination reaction and the whole process generates one proton from ionisation of the new carboxylic acid at C-8 and a second proton from ionisation of the 2-thiothiadizole moiety generated by a β-elimination of that group from the C-3 side chain ([Figure 3](#F3){ref-type="fig"}C).

![Calorimetric thermogram for the titration of penicillin G with NDM-1 in a single injection ITC assay and the determination of the intrinsic enthalpy of reaction (Δ*H*~int~)\
(**A**) Raw thermal power measured by titrating 20 μl of 1 mM penicillin G into 60 nM NDM-1 protein or buffer (control) at 25°C. (**B**) Determination of the intrinsic enthalpy change (Δ*H*~int~) of penicillin G catalysed by NDM-1 with linear regression of the apparent enthalpy change (Δ*H*~app~) for penicillin G over the protonation enthalpy of each buffer (Δ*H*~ion~) to give the intercept for Δ*H*~int~ and the slope for the number of protons (*n*) exchanged during catalysis.](bsr-38-bsr20180244-g2){#F2}

![Schematic illustration of the proposed catalytic mechanism of NDM-1 towards three β-lactam antibiotics, highlighting the difference in number of protons released.](bsr-38-bsr20180244-g3){#F3}

###### Thermodynamic and kinetic data of the hydrolysis of three β-lactam antibiotics catalysed by NDM-1 derived using ITC.

  Compound           Δ*H*~app~ (kcal/mol)   *n*            Δ*H*~int~ (kcal/mol)   *k*~cat~ (s^−1^)   *K*~M~ (μM)   *k*~cat~/*K*~m~ (s^−1^ μM^−1^)   *k*~cat~/*K*~M~-UV[^1^](#T1TFN1){ref-type="table-fn"} (s^−1^ μM^−1^)
  ------------------ ---------------------- -------------- ---------------------- ------------------ ------------- -------------------------------- ----------------------------------------------------------------------
  **Penicillin G**   −27.9 ± 0.01           −0.87 ± 0.10   −18.3 ± 0.73           54 ± 1             139 ± 12      0.39                             0.68
  **Cefazolin**      −28.3 ± 0.97           −1.89 ± 0.04   −5.20 ± 0.04           42 ± 1             237 ± 14      0.18                             −
  **Imipenem**       −32.5 ± 0.08           −1.24 ± 0.02   −18.4 ± 0.12           23 ± 1             168 ± 28      0.14                             0.21

From Yong et al. \[[@B15]\] using the traditional UV-spectroscopic assay. Reactions were performed at 30°C in buffer 10 mM HEPES, pH 7.5.

The calorimetric data for the titration of NDM-1 with penicillin G following a multiple injection method to obtain kinetic data is shown ([Figure 4](#F4){ref-type="fig"}A). The process involves 23 successive injections of antibiotic solution into NDM-1 solution. A time interval of 120 s allows the heat flow to reach a brief plateau after each injection to mimic steady-state conditions of reaction (the enzyme is fully saturated and \<5% of the substrate is depleted). Each injection of the substrate solution further increases the magnitude of heat change offset. The rate of heat change (d*Q*/d*t*) at each substrate concentration was determined as the displacement between the original baseline before the first injection and the new baseline after each injection. This value was then converted into enzyme turnover rates and fitted to the Michaelis--Menten equation to obtain the parameters *K*~M~ and *k*~cat~ ([Figure 4](#F4){ref-type="fig"}B). As shown in [Table 1](#T1){ref-type="table"}, NDM-1 has a higher preference for penicillin G (*K*~M~ = 139 μM) as substrate, followed by imipenem (*K*~M~ = 168 μM) and cefazolin (*K*~M~ = 237 μM), and the overall catalytic efficiency of NDM-1 towards penicillin G (*k*~cat~/*K*~M~ = 0.39 s^−1^ μM^−1^) is also 2-fold higher than that of the cefazolin (*k*~cat~/*K*~M~ = 0.18 s^−1^ μM^−1^) and almost 3-fold higher than that of imipenem (*k*~cat~/*K*~M~ = 0.14 s^−1^ μM^−1^), at pH 7.0, 25°C. These results agree with previous data obtained in a UV-spectroscopic assay where the *k*~cat~/*K*~M~ for penicillin G was determined as 0.68 s^−1^ μM^−1^, and the value for imipenem was determined as 0.21 s^−1^ μM^−1^, measured in 10 mM HEPES, pH 7.5 buffer at 30°C \[[@B15]\].

![Enzyme kinetics and inhibition of NDM-1 catalysed penicillin G hydrolysis using a multiple injection ITC assay and a UV-spectroscopic assay\
(**A**) Raw heat change observed in the calorimetric assay, obtained by titrating 10 mM penicillin G into 10 nM NDM-1 with 23 injections. (**B** and **D**) Global fitting of NDM-1 enzymatic activity in the absence (circles) and presence (triangles and squares) of compounds **7** and **8** as an enzyme inhibitor using data from the multiple injection ITC assay. Baseline displacement of the thermal power in [Figure 4](#F4){ref-type="fig"}(A) was converted into the reaction rate and plotted according to the Michaelis--Menten equation to obtain values of *K*~M~, *k*~cat~, *K*~ic~ and *K*~iu~. (**C** and **E**) IC~50~ of compounds **7** and **8** determined using a UV-spectroscopic method with inhibitor concentrations from 16 nM to 40 μM.](bsr-38-bsr20180244-g4){#F4}

After the calorimetric assay for steady-state kinetic study of NDM-1 was established, experiments were performed by pre-incubating different concentrations of inhibitor with NDM-1 for 30 min prior to substrate titration. As shown ([Figure 4](#F4){ref-type="fig"}B), there is a progressive decrease in enzyme turnover rates with increase in concentration of **7** from 0 to 5 μM. Global fitting of the data to the general inhibition equation gives a competitive inhibition constant *K*~ic~ of 2.17 ± 0.48 μM and a similar uncompetitive inhibition constant *K*~iu~ of 2.07 ± 0.06 μM, showing **7** is a potent mixed inhibitor of NDM-1. The IC~50~ value of **7**, determined using a conventional UV-spectroscopic method, compares well with our inhibition data from ITC experiments ([Table 2](#T2){ref-type="table"}), with an IC~50~ value of 1.13 ± 0.04 μM for this compound. Our results, in conjunction with a previous report that the presence of 100 μM of this compound was capable of reducing enzyme activity of a different class B1 IMP-1 towards imipenem up to 2%, with barely any effect on BcII, VIM-2, or VIM-4 from the same class of MβLs \[[@B37]\], highlights this compound as having a good degree of selectivity for enzymes within class B1 MβLs. By comparison, **8** showed a much weaker competitive inhibition constant of *K*~ic~ = 152 ± 6 μM and a slightly larger uncompetitive inhibition constant of *K*~iu~ = 5 ± 0.46 μM ([Figure 4C](#F4){ref-type="fig"} and [Table 2](#T2){ref-type="table"}), indicating the mechanism of **8** inhibition at pH 7.0 is predominantly uncompetitive, and the inhibitor binds to the enzyme--substrate complex instead of to the free enzyme. This *K*~iu~ is in good accord with the IC~50~ of 3.45 ± 0.26 μM for NDM-1 ([Figure 4E](#F4){ref-type="fig"}), and also in agreement with previous data that this compound is a broad-spectrum inhibitor of MβLs with strong inhibitory potency towards class B1 CcrA (*K*~i~ = 0.64 μM), class B2 ImiS (*K*~i~ = 7.1 μM) and class B3 L1 (*K*~i~ = 1.8 μM) \[[@B39]\]. Of the dicarboxylic acid compounds tested, **5** and **6** have the weakest inhibitory activity towards NDM-1, in a mainly competitive mode, with *K*~ic~ = 365 ± 72 μM and IC~50~ = 409 ± 16 μM for **5** and *K*~ic~ = 198 ± 50 μM and IC~50~ = 232 ± 5 μM for **6**. In addition, as a control, the *K*~ic~ of **1** was determined to be 1.36 ± 0.79 μM by ITC and the UV-spectroscopic IC~50~ was 2.38 ± 0.64 μM, which are consistent with previously reported values of *K*~i~ = 1.3 μM and IC~50~ = 7.9 μM \[[@B24],[@B25]\]. Taken together, the overall ranking of the tested inhibitors agrees well in both the ITC assay and the UV-spectroscopic assay, with **1, 7** and **8** being the most potent single-digit micro-molar inhibitors of NDM-1, while **5** and **6** were significantly weaker inhibitors by almost two orders of magnitude.

###### Inhibition of NDM-1 by carboxylic acid compounds

  Inhibitor   IC~50~ (μM)[^1^](#T2TFN1){ref-type="table-fn"}   *K*~ic~ (μM)[^2^](#T2TFN2){ref-type="table-fn"}   *K*~iu~ (μM)[^2^](#T2TFN2){ref-type="table-fn"}
  ----------- ------------------------------------------------ ------------------------------------------------- -------------------------------------------------
  **1**       2.38 ± 0.64                                      1.36 ± 0.79                                       178 ± 21
  **5**       409 ± 16                                         365 ± 72                                          993 ± 107
  **6**       232 ± 5                                          198 ± 50                                          638 ± 94
  **7**       1.13 ± 0.04                                      2.17 ± 0.48                                       2.07 ± 0.06
  **8**       3.45 ± 0.26                                      152 ± 6                                           5 ± 0.46

Data were from the UV-spectroscopic assay in the present study. Experiments were performed at 25°C in buffer 50 mM Tris--HCl, pH 7.0, 100 mM NaCl.

Data were from the ITC inhibition assay in the present study. Experiments were performed at 25°C in buffer 50 mM Tris--HCl, pH 7.0, 100 mM NaCl.

A cell-based ITC assay was further performed with the more potent compounds **7** and **8**, using **1** as a reference, to ascertain whether these inhibitors can retard NDM-1 hydrolysis of imipenem in a cellular environment using live bacteria, in a manner similar to the reported UV--vis approach \[[@B49]\]. The raw data of titration of cell suspensions of a carbapenemase-negative strain (ATCC 25922) with imipenem ([Figure 5](#F5){ref-type="fig"}A) reveal negligible heat change. In comparison, titration of imipenem into cell suspensions of an NDM-1--positive clinical *E. coli* strain (*E. coli*--NDM-1) led to a considerable negative change of heat-flow, much like the calorimetric curves with purified NDM-1 ([Figure 5](#F5){ref-type="fig"}B). This strongly suggests that the derived heat-change in the calorimetric assay with *E. coli*--NDM-1 arises from enzyme-catalysed hydrolysis of imipenem. Cell-based inhibition assays were then performed by titrating imipenem with *E. coli*--NDM-1 in the presence of 400 μM of compounds **1, 7** and **8** ([Figure 5](#F5){ref-type="fig"}B). All tested compounds were capable of inhibiting the turnover rate of imipenem and postponing the time required for complete consumption of the substrate, with an efficacy in the order of **7** \> **1** \> **8**. The MICs of imipenem on this clinical *E. coli*--NDM-1 isolate, in the absence and presence of compounds **1, 7** and **8**, were next determined ([Table 3](#T3){ref-type="table"}). The addition of 200--400 μM inhibitors alone showed no effect on bacterial growth, indicating these compounds have no antimicrobial activity at concentrations tested. However, when **7** and **8** were administered in combination with imipenem, the resistant strain was re-sensitised towards imipenem. The presence of 400 μM of **7** was able to restore the susceptibility of *E. coli*--NDM-1 towards imipenem, by lowering the MICs of imipenem from 16 to 1 μg/ml. Compound **8** at 400 μM reduced the MICs by 2-fold and shows a weaker synergy with imipenem. Surprisingly, reference compound **1** failed to show any synergistic effect with imipenem at the tested concentrations, notwithstanding its superior inhibitory potency in the above *in vitro* experiments**.** The possibility of **1** inactivation due to slow oxidation of --SH during overnight incubation with bacterial suspensions needs to be investigated.

![Heat flow data for the inhibition of NDM-1 in a cell-based calorimetric assay\
(**A**) Raw calorimetric trace for titrating imipenem (20 μl 1 mM) into suspensions of a reference *E. coli* (ATCC25922, no β-lactamase production) at OD = 4 in Tris--HCl buffer. (**B**) Overlaid calorimetric traces of titrating imipenem (20 μl 1 mM) into suspensions of an NDM-1-producing clinical *E. coli* strain at OD = 4 in the absence and presence of 400 μM inhibitors **1, 7** and **8**. Control experiment was performed by injecting buffer into bacterial suspensions.](bsr-38-bsr20180244-g5){#F5}

###### MICs of a clinical *E. coli*--NDM-1 strain towards imipenem and imipenem-inhibitor combination

                            MICs (μg/ml) of imipenem in combination with **1, 7** and **8** at various concentrations        
  ------------------------- ------------------------------------------------------------------------------------------- ---- ----
  *E.coli*--NDM-1           16                                                                                               
  *E.coli*--NDM-1 + **1**                                                                                               16   16
  *E.coli*--NDM-1 + **7**                                                                                               4    1
  *E.coli*--NDM-1 + **8**                                                                                               16   8

Conclusion {#sec4}
==========

NDM-1 is a class B1 metallo-β-lactamase commonly found in clinical multi-drug resistant pathogens that catalyse the hydrolysis of β-lactam antibiotics, leading to inactivation of these bactericides. We have used a new ITC approach to study the thermodynamic data and hydrolytic activity of NDM-1 towards individual β-lactams from three families, penicillin G, cefazolin and imipenem, coupled to the inhibitory potency of four low-molecular-weight dicarboxylic acid compounds to promote their activity. Our results reveal that NDM-1 catalysed hydrolysis of penicillin G, cefazolin and imipenem follow different mechanisms, with cefazolin showing a greatly reduced intrinsic enthalpy change as well as release of a second proton during β-lactamase turnover. Both ITC and UV-spectroscopic experiments identify pyridine-2,6-dicarboxylic acid and thiazolidine-2,4-dicarboxylic acid as good inhibitors of NDM-1. These compounds also show good potency in inhibiting NDM-1 hydrolysis of imipenem at the cellular level and re-sensitising a clinical strain of *E. coli*--NDM-1 towards imipenem, suggesting they are promising leads for future development of more potent inhibitors of NDM-1. The possibility that the activity of pyridine-2,6-dicarboxylic acid and thiazolidine-2,4-dicarboxylic acid results from zinc coordination is clearly reminiscent of the outstanding development of ACE inhibitors such as Captopril from the work of Ondetti and Kushman and merits active development \[[@B50]\], while recent crystallographic analysis has identified the sulphur atom of Captopril bridging the two zinc atoms in SMB-1 (PDB: 5aya), and bidentate coordination to a single zinc atom involving sulphur has been exemplified for blaNDM-1 (PDB: 5a5z) \[[@B51]\], and underpins current work based on cysteine for inhibitor development \[[@B52]\]. The well-known power of pyridinecarboxylic acids to zinc has been exemplified by picolinic acid for ACC oxidase \[[@B53]\], but there is no structural report of enzymatic zinc chelation by compound **7**. It is thus reasonable to propose that the inhibitory effect of compounds **7** and **8** may result from a combination of monodentate and bidentate coordination to the two zincs in NDM-1 and merits detailed structural analysis. Compared with D-(−)-tartaric acid and fumaric acid, the superior inhibitory potency of pyridine-2,6-dicarboxylic acid and thiazolidine-2,4-dicarboxylic acid with NDM-1 are likely ascribed to two aspects. Firstly, constrains imposed by the pyridine and thiazolidine rings may help to arrange the attached carboxylate groups for more favourable hydrogen-bonding/ionic interactions with enzyme active site residues. Secondly, the pyridine and thiazolidine rings may also directly contribute to stronger binding by making hydrophobic interactions with nonpolar residues at NDM-1 active site. In the perspective of generating broad-spectrum inhibitors of MβLs for combination therapy, the mechanistic complexity of antibiotic hydrolysis and different modes of inhibitor binding, as highlighted in this work with NDM-1, pose a huge challenge. This work also endorses the ITC assay as a reliable method to obtain kinetic data on enzyme catalysis and inhibition at both protein and cellular levels, with the additional advantage of providing important thermodynamic information on enzyme catalysis. The ITC assay presented here is expected to be adopted as a general method to facilitate mechanistic studies of other clinical β-lactamases and the evaluation of potential inhibitors.
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